Florzolotau F-18 clinical trials
Also written F-18 PMPBB3 and [18F]APN-1607.
How each study uses florzolotau F-18 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the florzolotau F-18 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 2 |
| 2021 | 2 |
| 2022 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 5
Chang Gung Memorial Hospital (3) · JYAMS PET Research & Development Limited (2) · APRINOIA Therapeutics, LLC (1) · APRINOIA Therapeutics (1) · Invicro (1) · Nanjing First Hospital, Nanjing Medical University (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Radiopharmaceuticals source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 2 in phase 3
Studies that test florzolotau F-18, phase 3 first.
- Dec 2026Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive FunctionPhase 3 · JYAMS PET Research & Development Limited
- Apr 2027Evaluate the Concordance Between PET Imaging of [18F]-APN-1607 Injection and Postmortem Brain Tissue Tau Pathology in Individuals With HV and MCI or AD.Phase 3 · JYAMS PET Research & Development Limited
Studies
Open first, then newest update. How each study uses florzolotau F-18 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- Evaluate the Concordance Between PET Imaging of [18F]-APN-1607 Injection and Postmortem Brain Tissue Tau Pathology in Individuals With HV and MCI or AD.RecruitingPhase 3JYAMS PET Research & Development LimitedNCT07752784Written as [18F]-APN-1607
- Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive FunctionRecruitingPhase 3JYAMS PET Research & Development LimitedNCT07422857Written as [18F]-APN-1607
- Clinical Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease PatientsRecruitingEarly Phase 1Nanjing First Hospital, Nanjing Medical UniversityNCT05043675Written as [18F]APN-1607
- [18F]APN-1607 PET in Subjects With AD Compared to HCCompletedPhase 3APRINOIA TherapeuticsNCT05542953Written as [18F]APN-1607
- Evaluation of [18F]APN-1607 as a PET BiomarkerCompletedPhase 1InvicroNCT05005819Written as [18F] APN-1607
- Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients Compared With Healthy SubjectsActive, not recruitingPhase 2APRINOIA Therapeutics, LLCNCT04141150Written as [18F]APN-1607
- Topography Staging and Dual Phase Image Quantification of Tau PET in Cognitive Impairment SubjectsStatus unknownPhase 2Chang Gung Memorial HospitalNCT04169126Written as F-18 PMPBB3
- Alzheimer's Disease: Clinical Investigation and Neuroimage Studies Including 18F-PM-PBB3 and 18F-florbetapir (AV-45) PET ExaminationStatus unknownPhase 2Chang Gung Memorial HospitalNCT04305210Written as F-18 PMPBB3
- 18F-PM-PBB3 PET Study in Tauopathy Including Alzheimer's Disease, Other Dementias and Normal ControlsCompletedEarly Phase 1Chang Gung Memorial HospitalNCT03625128Written as F-18
Codes
What other systems call florzolotau F-18 · ClinicalTrials.gg INT014970
- UNII (FDA) 51M993JIQ4FLORZOLOTAU F-18One source FDA
- NCI Thesaurus C190341Florzolotau F-18One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 51M993JIQ4 | FLORZOLOTAU F-18 | One source FDA |
| NCI Thesaurus | C190341 | Florzolotau F-18 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.